Clintec’s research site boost at Scotland HQ

By Flora Southey contact

- Last updated on GMT

Clintec International has opened a centre of excellence for clinical research and quality assurance capabilities as part of its headquarters expansion in Glasgow, Scotland.

A spokesperson told us the expansion, which adds 4327 sq. ft. to the contract research organisation’s (CRO) site, is attracting new clients.

“Global pharma are very interested in the functional outsourcing/FSP ​[functional service provision] capabilities which Clintec has, and the expanded Glasgow office supports these clients in analytics, functional resourcing, client relations and quality assurance.”

“We are getting more and more requests from small/medium sized biotech companies mainly from the US who are tapping into our capabilities and expertise especially in the oncology and rare diseases area,” ​said the spokesperson.

New jobs

The Clintec spokesperson told us the expansion will create new jobs with varying skill requirements.

“Additional jobs are being created in most areas of our business in the Glasgow HQ including our clinical research functions such as Clinical Operations and Biometrics, alongside corporate functions including client relations and business development.”

“We are creating opportunities for experienced individuals as well as trainees, and are committed to developing the next generation of talent within clinical research,” ​said the spokesperson.

UK / US relationship

Clintec said the expanded headquarters will manage operations across Europe, and emerging territories including Turkey, the Middle East and Africa, as well in the US, where is it growing its client base.

“We have embarked on a long-term vision to develop a leading capability in North America.”

“There are strong business links between the UK and USA, and it has been a natural fit to fully support the US operation from the Glasgow HQ,” ​said the spokesperson.

Related news

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers